Feraheme regulatory update

Takeda said the Scottish Medicines Consortium recommended the restricted use of Rienso ferumoxytol on the National Health Service (NHS) in Scotland to treat iron deficiency anemia in non-hemodialysis-dependent adult patients with chronic kidney disease (CKD) when oral iron preparations are ineffective or cannot be used. The IV iron replacement therapy is approved in the EU to treat iron deficiency anemia in adult patients with CKD. Takeda has rights to the product from AMAG in Europe, Canada, Turkey and Asia-Pacific, excluding Japan, China and Taiwan, under an amended 2010 deal (see BioCentury, July 9, 2012). 3SBio has rights in China. ...